Annex

United Kingdom

In Table 1 of the Annex to Regulation (EU) No 37/2010, the following substance is inserted in alphabetical order:

Pharmacologically active substance Marker residue Animal species MRL Target tissues Other provisions(according to Article 14(7) of Regulation (EC) No 470/2009) Therapeutic classification
‘Tildipirosin Tildipirosin Bovine, caprine 400 μg/kg Muscle
Not for use in animals from which milk is produced for human consumption.

The MRL for muscle shall not apply to the injection site, where residue levels shall not exceed 11 500 μg/kg.

Provisional MRL shall expire on 1 January 2012.
Macrolide’
200 μg/kg Fat
2 000 μg/kg Liver
3 000 μg/kg Kidney
Porcine 1 200 μg/kg Muscle
The MRL for muscle shall not apply to the injection site, where residue levels shall not exceed 7 500 μg/kg.

Provisional MRL shall expire on 1 January 2012.

800 μg/kg Skin and fat
5 000 μg/kg Liver
10 000 μg/kg Kidney

Pharmacologically active substance	Marker residue	Animal species	MRL	Target tissues	Other provisions(according to Article 14(7) of Regulation (EC) No 470/2009)	Therapeutic classification
‘Tildipirosin	Tildipirosin	Bovine, caprine	400 μg/kg	Muscle	Not for use in animals from which milk is produced for human consumption. The MRL for muscle shall not apply to the injection site, where residue levels shall not exceed 11 500 μg/kg. Provisional MRL shall expire on 1 January 2012.	Macrolide’
			200 μg/kg	Fat
			2 000 μg/kg	Liver
			3 000 μg/kg	Kidney
		Porcine	1 200 μg/kg	Muscle	The MRL for muscle shall not apply to the injection site, where residue levels shall not exceed 7 500 μg/kg. Provisional MRL shall expire on 1 January 2012.
			800 μg/kg	Skin and fat
			5 000 μg/kg	Liver
			10 000 μg/kg	Kidney